Haematology and blood transfusion最新文献_第10页

Cellular pharmacokinetics of daunomycin in human leukemic blasts in vitro and in vivo. 道诺霉素在人白血病细胞体内体外药动学研究。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_22

M E Scheulen, B Kramer, M Skorzec, W K Reich

引用次数: 1

Determination of soluble interleukin-2 receptors after bone marrow transplantation. 骨髓移植后可溶性白介素-2受体的测定。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_13

W Siegert, O Josimovic-Alasevic, R Schwerdtfeger, C Schmidt, A Neubauer, G Henze, D Huhn, T Diamantstein

引用次数: 1

Double intensive consolidation chemotherapy (ICC) for acute myeloid leukemia. 双强化巩固化疗(ICC)治疗急性髓系白血病。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_54

J L Harousseau, N Milpied, J Briere, B Desablens, P Y Le Prise, N Ifrah, C Gandhour, P Casassus

引用次数: 6

Thrombin generation in acute myeloblastic leukemia. 急性髓母细胞白血病凝血酶的产生。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_68

R E Scharf, U Stoffels, W Schneider

引用次数: 0

Pretherapeutic drug testing in acute leukemias for prediction of individual prognosis. 急性白血病治疗前药物试验预测个体预后。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_53

B Lathan, M von Tettau, K Verpoort, V Diehl

引用次数: 18

Changes in clonal growth, immunophenotype, and morphology during a follow-up study of an acute lymphoblastic leukemia. 急性淋巴细胞白血病随访研究中克隆生长、免疫表型和形态学的变化。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_31

A Reichle, M Volkmann, K Pachmann, H Diddens, B Emmerich, J Rastetter

{"title":"Changes in clonal growth, immunophenotype, and morphology during a follow-up study of an acute lymphoblastic leukemia.","authors":"A Reichle, M Volkmann, K Pachmann, H Diddens, B Emmerich, J Rastetter","doi":"10.1007/978-3-642-74643-7_31","DOIUrl":"https://doi.org/10.1007/978-3-642-74643-7_31","url":null,"abstract":"Cells of a 21-year-old patient with acute lymphatic leukemia were analyzed for morphology and immunophenotype and for genotype consecutively during the course of disease. Initial therapy with the BMFT-ALL protocol (Bundesministerium für Forschung und Technologie) reduced leukemic cells only marginally. The following high-dose Ara-C, mitoxantrone (HAM) chemotherapy led to a cell reduction of 75% and to a drastic change in cell morphology from initially 90% blasts to mainly small lymphoid cells. Immunophenotype, which showed 90% CD7-positive cells in the beginning with a prevalence of helper (60%) over suppressor cells (15%) remained fairly constant until the onset of HAM chemotherapy, which led to a sharp fall and a subsequent slow increase in all T-cell markers. In contrast to pretherapeutic findings, CD7 was now only expressed on the small cells and not on blast cells. Southern blot analysis of the T-cell receptor configuration revealed an initially monoclonal population with rearranged T beta gene. A new band appearing during the clinically ineffective therapy was indicative for development of a second small population which did, however, not emerge in immunophenotype analysis. This second population was eliminated by the HAM chemotherapy, leaving back the initial clone responsible for the final fatal outcome. No activity of the multidrug resistance gene could be detected by Northern blotting.","PeriodicalId":12936,"journal":{"name":"Haematology and blood transfusion","volume":"33 ","pages":"159-65"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13311092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Consolidation therapy with high-dose cytosine arabinoside: experiences of a prospective study in acute myeloid leukemia. 大剂量阿拉伯糖胞嘧啶巩固治疗:急性髓系白血病的前瞻性研究经验。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_46

E Kurrle, G Ehninger, E Fackler-Schwalbe, M Freund, G Heil, D Hoelzer, H Link, B Löffler, A Lösch, P S Mitrou

引用次数: 11

Intensive induction therapy with behenoyl, cytosine arabinoside, daunorubicin, and 6-mercaptopurine followed by intensive consolidation with mitoxantrone, etoposide, vincristine, and intermediate-dose continuous cytarabine (M-85 protocol) for adult acute myelogenous leukemia. 成人急性髓性白血病的强化诱导治疗包括:behenoyl、胞嘧啶arabinoside、柔红霉素和6-巯基嘌呤，随后强化巩固治疗米托蒽醌、依托泊苷、长春新碱和中剂量连续阿糖胞苷(M-85方案)。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_55

R Ohno, S Yokomaku, M Okumara, M Tanimoto, Y Morishita, Y Morishima, Y Kodera, H Saito

引用次数: 0

Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia. 米托蒽醌、阿糖胞嘧啶和VP-16在36例复发和难治性急性髓性白血病中的应用。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_60

H Link, M Freund, H Diedrich, H Wilke, J Austein, M Henke, H Wandt, E Fackler-Schwalbe, G Schlimok, R Hoffmann

{"title":"Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia.","authors":"H Link, M Freund, H Diedrich, H Wilke, J Austein, M Henke, H Wandt, E Fackler-Schwalbe, G Schlimok, R Hoffmann","doi":"10.1007/978-3-642-74643-7_60","DOIUrl":"https://doi.org/10.1007/978-3-642-74643-7_60","url":null,"abstract":"Mitoxantrone in combination with VP-16 proved to be effective in refractory and relapsed acute myeloid leukemia (AML), with 42% of patients achieving complete remission (CR). The aim of this study was to assess whether the addition of cytosine arabinoside increased the response rate at a tolerable toxicity. The regimen consisted of mitoxantrone (M) 10 mg/m2 i.v. days 4-8, cytosine arabinoside (A) 100 mg/m2 continuous infusion days 1-8, and etoposide (VP-16) (V) 100-120 mg/m2 i.v. days 4-8 (MAV protocol) for relapsed and refractory AML. Thirty-six patients were treated, with a median age of 51 (20-73) years. For induction therapy one to two MAV cycles and for consolidation therapy two courses were scheduled. Twenty-one (58.3%) patients attained a complete remission (CR), with a median duration of 4.5 (1-12+) months. The median survival of all patients was 5.5 (0.5-15.5+) months. Four patients died in CR from chronic infections or after consolidation therapy with MAV. In evaluable patients, times to greater than 500 granulocytes/microliters and greater than 25,000 platelets/microliters were 23 (7-46) and 23 (6-44) days, respectively. In 54 evaluable MAV courses the following toxicity was observed (WHO grades 3/4): 26%, nausea and vomiting: 9%, hemorrhage; 6%, bilirubinemia; 11%, diarrhea; 22%, mucositis; 6%, local infection; 20%, septicemia; 13%, fever of unknown origin; 2%, cardiac arrhythmia; 7%, congestive heart failure. We conclude that MAV therapy is a highly active antileukemic combination with acceptable toxicity, which is recommended for further clinical trials in untreated AML.","PeriodicalId":12936,"journal":{"name":"Haematology and blood transfusion","volume":"33 ","pages":"322-5"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13334711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

Acute megakaryoblastic leukemia: a case report. 急性巨核细胞白血病1例。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_69

R Donhuijsen-Ant, C Schadeck-Gressel, U Schmidt, H Löffler, M Westerhausen, L D Leder

引用次数: 1